CCAAT/enhancer binding protein α (CEBPA) mutations are found in roughly 10% of AML patients [104], and only biallelic-mutated cases seem to be associated with favorable outcomes [105,106,107]. This evidence concerns the gene CEBPA and acute myeloid leukemia.